Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358124 · ClinicalTrials.gov registry record · Phase 4
Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 220
- Enrollment target
NCT00358124 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 220 participants.
The verdict
NCT00358124, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 220 participants
- Enrollment target
Study Summary
To compare the glycemic control, as measured by HbA1C, between insulin glargine and rosiglitazone add-on therapies in patients who fail oral combination of a sulfonylurea and metformin
Interventions
- DRUG metformin
- DRUG insulin glargine
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2001-01 |
| Est. Completion | 2002-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00358124
The ClinicalTrials.gov registry entry for NCT00358124 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which metformin is the first listed.
NCT00358124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00358124 about?
NCT00358124 is a clinical study titled "Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy". To compare the glycemic control, as measured by HbA1C, between insulin glargine and rosiglitazone add-on therapies in patients who fail oral combination of a sulfonylurea and metformin
What is the current status of trial NCT00358124?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2001-01. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00358124?
The interventions under investigation include: metformin (DRUG), insulin glargine (DRUG), rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00358124?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.